ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1241

Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries

Hugo Madariaga1, Juan Reyes2, Magda Gutierrez3, Dario Ponce de Leon4, Tatjana Lukic5 and Luisa Amador2, 1Centro Medico CEEN, Arequipa, Arequipa, Peru, 2Pfizer, Bogota, Cundinamarca, Colombia, 3Pfizer, Santiago, Region Metropolitana, Chile, 4PFIZER, LIMA, Peru, 5Pfizer Inc, New York, NY

Meeting: ACR Convergence 2020

Keywords: Cohort Study, comparative effectiveness, Patient reported outcomes, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: RA – Treatments Poster III: PROs, Biomarkers, Systemic Inflammation & Radiographs

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The objective of this study was to describe the efficacy, safety and patient reported outcomes in Latin-American patients with Rheumatoid Arthritis (RA) treated with tofacitinib 5mg (BID) or biological DMARDs (bDMARDs) after failure to respond to conventional DMARDs in real-life conditions. The primary objective of this study was to compare the disease activity measured by RAPID3 at 0- and 6-months follow-up.

Methods: This was a prospective and retrospective non-interventional study (NIS) comparing tofacitinib to bDMARDs treatments in patients with RA after failure of conventional DMARDs; the study was performed in 13 sites from Colombia and Peru between 2017 to 2019. Convenience sampling in the tofacitinib arm and randomized in the bDMARDs arm was performed. Demographic and clinical information was collected at baseline and follow up. The following questionnaires were applied at baseline and Month 6 (±1 month) of follow-up: RAPID3 (Routine Assessment of Patients Index Data) to measure Disease activity; HAQ-DI (Health Assessment Questionnaire) to measure Functional status; EQ-5D-3L (EuroQol Questionnaire) to measure Quality of life. Frequency of Adverse Events (AE) was taken from clinical records retrospectively and collected during visits when spontaneously reported. The clinical outcomes were adjusted through linear regression by demographic, clinical and access variables. Unadjusted and adjusted differences from baseline were reported in Standardized Mean Difference (SMD).

Results: Data from 100 RA patients treated with tofacitinib and 70 RA patients with bDMARDs (85% treated with etanercept, rituximab, tocilizumab and infliximab) was collected and patients were recruited between April 2017 and February 2019. At baseline, patients mean age was 53.53 years (SD 13.77), mean disease duration was 6.31 years (SD 7.01) and mean DAS28 was 5.48 (SD 2.97). There was a significant difference in the following baseline demographic and clinical characteristics of the patients: previous methotrexate therapy, complementary access mechanism and time to supply were higher in the tofacitinib group, while prednisolone treatment and concomitant use of leflunomide were higher in the biologics. At month 6, there was no statistical difference in the adjusted SMD [Standard Error] from baseline for tofacitinib versus bDMARDs for RAPID 3 (-0.20 [0.69] vs. -0.32 [0.71]), HAQ-DI (-0.56 [0.07] vs. -0.50 [0.08]), EQ-5D-3L (0.23 [0.06] vs. 0.29 [0.06]) and DAS28 (-3.86 [0.59] vs. -4.23 [0.61]). Patients with tofacitinib and biologics presented a similar proportion of non-serious AE (30.0% and 28.6%, respectively); there were two serious AE in the tofacitinib group (2.0%) that were not related to the treatment. These results have limitations (heterogeneity among groups, sample size) given the specific characteristics of NIS.

Conclusion: There were no differences between patients with RA treated with tofacitinib and biological DMARDs regarding the disease activity, quality of life and functional status. Tofacitinib had similar safety profile to biological DMARDs in Latin American RA patients.


Disclosure: H. Madariaga, Pfizer, 8; J. Reyes, Pfizer, 3; M. Gutierrez, Pfizer, 3; D. Ponce de Leon, Pfizer, 1; T. Lukic, Pfizer Inc, 1, 3; L. Amador, Pfizer, 3.

To cite this abstract in AMA style:

Madariaga H, Reyes J, Gutierrez M, Ponce de Leon D, Lukic T, Amador L. Patient-Reported Outcomes in Rheumatoid Arthritis Patients Treated with Tofacitinib or Biological DMARDs in Real Life Conditions in Two Latin America Countries [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/patient-reported-outcomes-in-rheumatoid-arthritis-patients-treated-with-tofacitinib-or-biological-dmards-in-real-life-conditions-in-two-latin-america-countries/. Accessed September 22, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-reported-outcomes-in-rheumatoid-arthritis-patients-treated-with-tofacitinib-or-biological-dmards-in-real-life-conditions-in-two-latin-america-countries/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology